Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older (Q47547115): Difference between revisions

From Wikidata

Jump to navigation Jump to search

Browse history interactively

← Older edit Newer edit →

@@ Property / author name string @@
-Ciprian Brisc
@@ Property / author name string: Ciprian Brisc / rank @@
-Normal rank
@@ Property / author name string: Ciprian Brisc / qualifier @@
-series ordinal: 11
@@ Property / author name string: Ciprian Brisc / reference @@
-stated in: Europe PubMed Central
PMC publication ID: 5815789
retrieved: 4 March 2018Timestamp +2018-03-04T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
reference URL: http://europepmc.org/abstract/PMC/5815789
-Timestamp
++2018-03-04T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After

Revision as of 16:33, 27 August 2024

scientific article published in December 2017

Language	Label	Description	Also known as
English	Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older	scientific article published in December 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older (English)

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

16

object named as

Ion Rogoveanu

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

1

object named as

Anca Trifan

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

2

object named as

Carol Stanciu

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

3

object named as

Liana Gheorghe

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

4

object named as

Speranta Iacob

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Manuela Curescu

5

object named as

Manuela Curescu

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Cristina Cijevschi Prelipcean

6

object named as

Cristina Cijevschi Prelipcean

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Gabriela Stefanescu

7

object named as

Gabriela Stefanescu

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Irina Gîrleanu

8

object named as

Irina Girleanu

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

9

object named as

Stefan Chiriac

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Cătălina Mihai

10

object named as

Catalina Mihai

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

11

object named as

Ciprian Brisc

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

12

object named as

Adrian Goldis

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

13

object named as

Ioan Sporea

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

14

object named as

Egidia Miftode

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

15

object named as

Simona Bataga

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

17

object named as

Carmen Preda

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Florin-Alexandru Căruntu

18

object named as

Florin Alexandru Caruntu

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Ana Maria Singeap

19

object named as

Ana-Maria Singeap

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

author name string

Adrian Goldis

12

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Ioan Sporea

13

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Egidia Miftode

14

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Simona Bataga

15

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Carmen Preda

17

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Florin Alexandru Caruntu

18

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Ana-Maria Singeap

19

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

language of work or name

0 references

publication date

1 December 2017

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

96

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

50

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

e9271

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Global distribution and prevalence of hepatitis C virus genotypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

22 May 2018

Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

14 August 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

14 August 2018

EASL Recommendations on Treatment of Hepatitis C 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5815789

1 December 2018

EASL Recommendations on Treatment of Hepatitis C 2016

1 reference

https://pubmed.ncbi.nlm.nih.gov/29390377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/MD.0000000000009271

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

4 March 2018

http://europepmc.org/abstract/PMC/5815789

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47547115&oldid=2237695062"